ANNX Stock Summary and Trading Ideas (Annexon | NASDAQ:ANNX)

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Annexon trades on the NASDAQ stock market under the symbol ANNX.

As of January 27, 2025, ANNX stock price declined to $3.87 with 1,676,194 million shares trading.

ANNX has a beta of 1.78, meaning it tends to be more sensitive to market movements. ANNX has a correlation of 0.06 to the broad based SPY ETF.

ANNX has a market cap of $412.52 million. This is considered a Small Cap stock.

In the last 3 years, ANNX traded as high as $8.43 and as low as $1.57.

The top ETF exchange traded funds that ANNX belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.

ANNX has underperformed the market in the last year with a price return of -14.0% while the SPY ETF gained +24.4%. ANNX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -47.7% and -21.7%, respectively, while the SPY returned +3.9% and +3.1%, respectively.

ANNX support price is $3.93 and resistance is $4.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANNX shares will trade within this expected range on the day.